🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million infections each year. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Data and Global Access

As per results published in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which uses an injection and a pill. The trial enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have expressed optimism. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered crucial to alleviate the strain of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.